GlassScriptPhysician profile
Alyson B Simpson
NPI 1538288162
$9,635.46
in general payments reported to CMS, 2019-2025
40 companies · $2,545 in 2025
The $2,545 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $174 · 2021: $1,035 · 2022: $1,537 · 2023: $1,825 · 2024: $1,670 · 2025: $2,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,958 · Consulting Fee: $47.27 · Education: $33.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,957.98 |
| Consulting Fee | $47.27 |
| Education | $33.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,083.45 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $841.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $833.80 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $818.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $633.52 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $497.43 | 2019-2025 | Xolair |
| Kaleo, INC. | $421.33 | 2019-2024 | Auvi-Q |
| Amgen INC. | $410.28 | 2021-2025 | Tezspire, Actimmune |
| Grifols USA, LLC | $347.40 | 2021-2025 | Xembify |
| Pfizer INC. | $313.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $279.49 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.88 | 2021-2023 | Dupixent |
| Optinose US, INC. | $234.85 | 2020-2025 | |
| Pharming Healthcare, INC. | $199.56 | 2019-2023 | Ruconest |
| Biocryst US Sales Co., LLC | $193.53 | 2022-2025 | Orladeyo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyson Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.